Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise fix tiny muscle blood vessels in COPD?

NCT ID NCT02040363

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how exercise training affects the growth and maturation of tiny blood vessels in the leg muscles of people with COPD. Researchers will compare healthy volunteers and COPD patients doing different exercise intensities for 5 to 10 weeks. The goal is to understand why COPD patients have trouble building new blood vessels with exercise, which may limit their ability to be active.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise training
What this could lead to
If successful, this could help design better exercise programs for COPD patients to improve muscle function and quality of life.
What could go wrong
This is a small, early-stage study with only 22 participants, so results may not apply to all COPD patients. It focuses on biological markers, not direct health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Start date

Jan 2014

Finished

Aug 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 78 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * COPD patients : * FEV1\<80%pred. * non exacerbation during the past 4 weeks * no oxygen therapy, - Healthy subjects: * \<150min/week of moderate-to-vigorous physical activity, * Voorrips score \<9 Exclusion Criteria: * Unstable comorbidity * Long term oxygen therapy or ventilation * Rehabilitation program during the past 12 months * nutritional supplementation during the past 4 weeks * allopurinol or N-acetylcystein during the past 4 weeks * long corticosteroid treatment during the past 6 months * hyperreactivity to xylocain * anticoagulant or platelet aggregation inhibitors treatment * participation to an other research study-pregnancy or impossibility to provide informed consent, ...

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD Peripheral muscle dysfunction

Contacts and locations

Locations

  • Department of clinical Physiology - University Hospital

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.